Dilated Cardiomyopathy
Conditions
Keywords
dilated cardiomyopathy, immunoadsorption
Brief summary
Dilated cardiomyopathy (DCM) causes significant morbidity and mortality and is the third most common cause of heart failure and the most frequent reason for heart transplantation. The etiology of dilated cardiomyopathy(DCM) is complex. There is a growing body of literature suggesting that the humoral immune system activation and autoantibodies against myocardial generation play an important role in the progression of DCM. At present immunoadsorption technology has been successfully applied in autoimmune antibody removal treatment of a variety of diseases. And some applications of immunoadsorption(IA) in patients with DCM showed that immunoadsorption(IA) can indeed reduce the autoantibodies, improve symptoms and prognosis, but additional research is needed to identify indications and instruments for the IA treatment of DCM.
Detailed description
40 patients randomly divided into 2 groups： experimental group and control group experimental group： Device: protein A immunoadsorption protein-A immunoadsorption for 5 days and i.v.(intravenous injection) IgG(Immunoglobulin G）（0.5g/kg Body weight） substitution control group： non intervention
Interventions
PROCEDUREprotein A immunoadsorption
protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Dilated cardiomyopathy * LVEF \<= 40% determined by contrast echocardiography * NYHA(New York Heart Association) class II - IV * Age 18-70 * Disease duration: symptomatic heart failure ≥ 6 months prior to screening date * Treatment with Angiotensin-Converting Enzyme inhibitors(ACEI) or angiotensin II receptor blockers (ARB), beta-blockers, and aldosterone antagonists (the latter at the discretion of the attending physician), for at least 6 months and at stable doses for at least 2 months prior to screening date. * β1 adrenergic receptor antibody positive * The patient's informed consent
Exclusion criteria
* NYHA class IV patients who are bed-ridden and dependent upon parenteral medication * Cardiac insufficiency resulting from another basic disease (e.g. coronary artery disease, ≥50% stenosis of major vessel as ascertained by coronary angiography performed more recent than three years before screening date, hypertensive heart disease, or valvular defects \>second degree * History of myocardial infarction * Acute myocarditis according to Dallas criteria * Endocrine disorder excluding insulin-dependent diabetes mellitus * Implanted cardiac defibrillator (ICD) \<1 month before screening date * Cardiac resynchronization therapy (CRT) \<6 months before screening date * I.v. medication with inotropic drugs, vasodilators or repeated (\>1/day) i.v. administration of diuretics. * Active infectious disease, or signs of ongoing infection with C-reactive protein(CRP) \>10mmol/L * Impaired renal function (serum creatinine \>220 µmol/L) * Any disease requiring immunosuppressive drugs * Anaemia (haemoglobin below 90 g/L) due to other causes than congestive heart failure(CHF) * Pregnancy or lactation, or childbearing potential without appropriate contraception * Alcohol or drug abuse * Presence of a malignant tumour, or remission of malignancy \< 5 years * Refusal of the patient to provide consent * Suspected poor capability to follow instructions and cooperate * Another life-threatening disease with poor prognosis (survival less than 2 years) * Participation in any other clinical study within less than 30 days prior to screening date * Previous treatments with IA or immunoglobulin * Contraindications for application of the echocardiography contrast agent used (in accordance to the product specification).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Left ventricular ejection fraction (LVEF) at rest | six months | determined by contrast echocardiography |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| LVEF at rest | 1 year | determined by contrast echocardiography |
| Reduction of brain natriuretic peptides (BNP) or N-terminal pro-Brain Natriuretic Peptide(NT pro-BNP) | 6 months | — |
Countries
China
Outcome results
None listed